Microbiome Therapeutics (MBT) was founded in 2009 as NuMe Health by John Elstrott, Chairman; Dale Pfost, CEO and Mark Heiman, CSO. Our focus on the emerging science of the microbiome has increased over the past five years, while Mark Heiman has become a leader in the field. The company has undertaken two successful clinical trials and is preparing to launch its first product, referred to as NM504.